NASDAQ · NRIX
Nurix Therapeutics, Inc.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
Loading market information…
NASDAQ · SNDX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Syndax Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.49. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Syndax Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | -$0.98+5.77% vs estimate | $20.04M+8.06% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | -$1.10-1.85% vs estimate | $7.68M-39.93% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$0.98+13.27% vs estimate | $12.50M-89.15% vs estimate |
|---|
KEEP COMPARING
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$18.61+$0.22 (+1.2%)
Arcus Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.37% below the high.
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
$28.71-$0.19 (-0.66%)
Zymeworks Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.39% below the high.
$4.77+$0.18 (+3.92%)
Nuvation Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.08% below the high.
$17.39+$1.33 (+8.28%)
Replimune Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.19% below the high.
$8.99-$0.31 (-3.33%)
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$2.29-$0.07 (-2.97%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.11% below the high.
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $36.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
